Bydureon: Amylin Diabetes Drug Not Yet Approved By FDA

Bydureon: Amylin Diabetes Drug Not Yet Approved By FDA – Drugs company, Amylin Pharmecuticals Inc. yesterday released a statement to inform that the United States Food and Drug Administration had declined to approve their diabetes drug Bydureon because they was more tests to be run on it before they will approve it.

Originally, it was thought that a decision would be made on the drug by the US Food and Drug Administration as early as this week. However, the FDA have decided that they would like a QT test, which involves seeing how the drug affects patients hear rate.

As well as this, the FDA also requested the results of a study which would evaluate the efficiency of the drug, as well as its safety. The company who have produced the diabetes drug have said that they are aiming to respond to the FDA’s requests by the end of next year.

It is not yet clear whether or not this drug will be approved by the Food and Drug Administration. However, there have been similar drugs which are now on the market after being approved by the FDA.

If the drug does get through the approval stages then it could potentially be helpful to millions of people all over the United States, and possibly further. The FDA are awaiting response, and the testing is likely to continue from there, but many people are hopeful that the outcome will be a positive one.

Leave a Comment